Mirae Asset Global Investments Co., Ltd. Catalyst Pharmaceuticals, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$13.18 - $17.11 $92 - $119	-7 Reduced 0.01%	57,167 $911,000
Q4 2023 Jan 24, 2024	SELL	$11.78 - $17.29 $20,049 - $29,427	-1,702 Reduced 2.89%	57,174 $961,000
Q3 2023 Oct 26, 2023	SELL	$11.69 - $15.02 $93,929 - $120,685	-8,035 Reduced 12.01%	58,876 $688,000
Q2 2023 Aug 10, 2023	BUY	$11.5 - $18.08 $78,740 - $123,793	6,847 Added 11.4%	66,911 $899,000
Q1 2023 May 04, 2023	BUY	$14.34 - $21.05 $270,667 - $397,318	18,875 Added 45.83%	60,064 $995,000
Q4 2022 Feb 09, 2023	BUY	$12.25 - $19.5 $16,500 - $26,266	1,347 Added 3.38%	41,189 $766,000
Q3 2022 Nov 10, 2022	BUY	$7.06 - $15.52 $86,414 - $189,964	12,240 Added 44.34%	39,842 $511,000
Q2 2022 Jul 26, 2022	BUY	$6.23 - $8.57 $171,960 - $236,549	27,602 New	27,602 $193,000

326

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.12B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.